计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B126145-5mg |
5mg |
现货 ![]() |
| |
| B126145-10mg |
10mg |
现货 ![]() |
| |
| B126145-25mg |
25mg |
现货 ![]() |
| |
| B126145-100mg |
100mg |
现货 ![]() |
|
| 别名 | [4-[[1-(3-氟苄基)-1H-吲唑-5-基]氨基]-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基]氨基甲酸(S)-吗啉-3-基甲酯 |
|---|---|
| 英文别名 | UNII-04201GDN4R | BMS 599626 | Carbamic acid, N-(4-((1-((3-fluorophenyl)methyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo(2,1-F)(1,2,4)triazin-6-yl)-, (3S)-3-morpholinylmethyl ester | Mometasona [Spanish] | NCGC00346483-05 | NCGC00346483-11 | UCB-L-060 | [(3 |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | AC480 (BMS-599626) |
| 生化机理 | BMS-599626 是人类表皮生长因子受体 1 和 2(HER1 和 HER2,IC50 分别为 20 和 30 nM)的强效抑制剂。BMS599626 可抑制多种表达 HER 的癌细胞株的增殖,包括表达 HER2 的乳腺癌细胞株,但不影响 HER 阴性癌细胞株的增殖率。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 受体蛋白-酪氨酸激酶 erbB-4 抑制剂 |
| 产品介绍 |
AC480 (BMS-599626)是 HER1和HER2选择性高效抑制剂,IC50分别为20 nM和30 nM,比针对VEGFR2,c-Kit,Lck,MET的抑制性强100倍以上。 AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. |
| 纯度 | ≥98% |
| ALogP | 2.8 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504765465 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate |
| INCHI | 1S/C27H27FN8O3/c1-17-23(34-27(37)39-15-22-14-38-8-7-29-22)13-36-25(17)26(30-16-32-36)33-21-5-6-24-19(10-21)11-31-35(24)12-18-3-2-4-20(28)9-18/h2-6,9-11,13,16,22,29H,7-8,12,14-15H2,1H3,(H,34,37)(H,30,32,33)/t22-/m0/s1 |
| InChi Key | LUJZZYWHBDHDQX-QFIPXVFZSA-N |
| Smiles | CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F |
| Isomeric SMILES | CC1=C2C(=NC=NN2C=C1NC(=O)OC[C@@H]3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F |
| 分子量 | 530.55 |
| Reaxy-Rn | 18544659 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=18544659&ln= |
| 溶解性 | DMSO 113 mg/mL Water <1 mg/mL Ethanol 20 mg/mL |
|---|---|
| 敏感性 | 对热敏感 |
| 分子量 | 530.600 g/mol |
| XLogP3 | 2.800 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 9 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 530.219 Da |
| 单同位素质量Monoisotopic Mass | 530.219 Da |
| 拓扑极表面积Topological Polar Surface Area | 120.000 Ų |
| 重原子数Heavy Atom Count | 39 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 828.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Gavai AV, Fink BE, Fairfax DJ, Martin GS, Rossiter LM, Holst CL, Kim SH, Leavitt KJ, Mastalerz H, Han WC et al.. (2009) Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.. J Med Chem, 52 (21): (6527-30). [PMID:19821562] |
| 2. Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF et al.. (2012) Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.. Ann Oncol, 23 (2): (463-71). [PMID:21576284] |